<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T00:37:40Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12377" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12377</identifier><datestamp>2026-10-18T21:13:19Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma</dc:title><dc:creator>Issin, Gizem</dc:creator><dc:creator>Sayar, İlyas</dc:creator><dc:creator>Demir, Fatih</dc:creator><dc:creator>Bakkaloğlu, İrem Güvendir</dc:creator><dc:creator>Gamsizkan, Mehmet</dc:creator><dc:creator>Yildiz, Zeliha</dc:creator><dc:creator>Yilmaz, İsmail</dc:creator><dc:creator>Özmen, Sevilay Akalp</dc:creator><dc:creator>Çağatay, Diren Vuslat</dc:creator><dc:creator>Zemheri, Itır Ebru</dc:creator><dc:creator>Demiriz, Murat</dc:creator><dc:creator>Günald, Armağan</dc:creator><dc:subject>abnormal e-cadherin expression</dc:subject><dc:subject>abnormal p53 expression</dc:subject><dc:subject>CDH1 mutation</dc:subject><dc:subject>EBV associated gastric cancer</dc:subject><dc:subject>microsatellite instability</dc:subject><dc:subject>molecular classification of gastric carcinoma</dc:subject><dc:subject>B7-H1 Antigen</dc:subject><dc:subject>Carcinoma</dc:subject><dc:subject>Epstein-Barr Virus Infections</dc:subject><dc:subject>Herpesvirus 4, Human</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Immunohistochemistry</dc:subject><dc:subject>In Situ Hybridization</dc:subject><dc:subject>Prognosis</dc:subject><dc:subject>Stomach Neoplasms</dc:subject><dc:subject>Tumor Suppressor Protein p53</dc:subject><dc:subject>epidermal growth factor receptor 2</dc:subject><dc:subject>programmed death 1 ligand 1</dc:subject><dc:subject>protein p53</dc:subject><dc:subject>uvomorulin</dc:subject><dc:subject>adult</dc:subject><dc:subject>age</dc:subject><dc:subject>Article</dc:subject><dc:subject>cancer prognosis</dc:subject><dc:subject>cancer size</dc:subject><dc:subject>cancer staging</dc:subject><dc:subject>cancer survival</dc:subject><dc:subject>clinical feature</dc:subject><dc:subject>epithelial mesenchymal transition</dc:subject><dc:subject>Epstein Barr virus</dc:subject><dc:description>Background/Aim: Gastric carcinoma (GC) is a highly heterogeneous disease with many subtypes that have different morphologic and molecular characteristics. In the current study, we analyzed immunohistochemical (IHC) and in situ hybridization (ISH) features of GCs and evaluated their association with prognosis and clinicopathological features. Materials and Methods: Three hundred cases analyzed by IHC and ISH for microsatellite stability, p53, e-cadherin, HER2, PD-L1 expression, and Epstein-Barr virus (EBV) status. Cases were classified into five subgroups based on expression profile. The relationships between subgroups, clinicopathological features, and survival were determined. Results: Ten (3.3%) cases were classified as EBV-associated, 45 (15%) as microsatellite instable (MSI), 73 (24.3%) as EBV–/microsatellite-stable (MSS)/epithelial−mesenchymal−transformation (EMT)-like, 75 (25%) as EBV–/MSS/non-EMT-like/p53+, and 97 (32.3%) as EBV–/MSS/non-EMT-like/p53–. The MSI subtype had the best overall survival (OS). In contrast, the EBV–/MSS/EMT-like subtype had the poorest OS. The MSI subtype was also related with old age of the patient and antrum-corpus localized tumors, whereas the EBV–/MSS/EMT-like was associated with young age, larger tumor size, and advanced stage presentation. PD-L1 positivity is highly correlated with MSI and EBV-associated subtypes. Conclusion: Our data demonstrated a link between IHC/ISH characteristics of GC and clinical outcomes. IHC/ISH based molecular classification may be helpful in predicting the survival. © 2023 by Begell House, Inc.</dc:description><dc:publisher>Begell House Inc.</dc:publisher><dc:date>2023</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/12377</dc:identifier><dc:identifier>https://doi.org/10.1615/jenvironpatholtoxicoloncol.2023047662</dc:identifier><dc:identifier>0731-8898</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Environmental Pathology, Toxicology and Oncology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12377</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>